Osteoporosis Therapeutics

Osteoporosis Therapeutics

Osteoporosis Therapeutics market worldwide is projected to grow by US$2.5 Billion, driven by a compounded growth of 3%. Bisphosphonates, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.2%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$6.9 Billion by the year 2025, Bisphosphonates will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 2.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$153.9 Million to the region's size and clout in the next 5 to 6 years. Over US$193.2 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Bisphosphonates will reach a market size of US$1.3 Billion by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.9% over the next couple of years and add approximately US$229.1 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include among others, Alergan Plc. (Ireland); Amgen, Inc. (US); Chugai pharmaceutical (Japan); Daiichi Sankyo Co., Ltd.(Japan); Egalet Corporation (USA); Eisai Co., Ltd. (Japan); Eli Lilly and Company (US); F. Hoffmann-La Roche Ltd. (Switzerland);

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
A Prelude to Osteoporosis
Select Approved Drugs for Treatment of Osteoporosis
Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
Global Competitor Drug Sales
Sales of Leading Osteoporosis Therapeutics: 2018
Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
Select Recent Osteoporosis Drug Approvals
2. FOCUS ON SELECT PLAYERS
Amgen, Inc. (USA)
Chugai Pharmaceutical Co., Ltd. (Japan)
Daiichi Sankyo Co., Ltd. (Japan)
Eisai Co., Ltd. (Japan)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Merck & Co. Inc. (USA)
Novartis International AG (Switzerland)
Pfizer, Inc. (USA)
Radius Health, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India
% of Women Affected by Osteoporosis
Osteoporosis – Factsheet
Osteoporosis in Men
Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
Changing Lifestyle Impacting Bone Health
Recommended Daily Intake of Calcium and Vitamin D
Increasing Awareness Related to Osteoporosis Care
New Product Launches Foster Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: Osteoporosis Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 2: Osteoporosis Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
TABLE 3: Osteoporosis Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
TABLE 4: Bisphosphonates (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 5: Bisphosphonates (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 6: Bisphosphonates (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
TABLE 7: Parathyroid Hormone Therapy (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
TABLE 8: Parathyroid Hormone Therapy (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
TABLE 9: Parathyroid Hormone Therapy (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
TABLE 10: Calcitonin (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
TABLE 11: Calcitonin (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
TABLE 12: Calcitonin (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 13: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
TABLE 14: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
TABLE 15: Selective Estrogen Inhibitors Modulator (SERM) (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
TABLE 16: Rank Ligand Inhibitors (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 17: Rank Ligand Inhibitors (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 18: Rank Ligand Inhibitors (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 19: Oral (Route of Administration) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
TABLE 20: Oral (Route of Administration) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
TABLE 21: Oral (Route of Administration) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
TABLE 22: Injectables (Route of Administration) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
TABLE 23: Injectables (Route of Administration) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
TABLE 24: Injectables (Route of Administration) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 25: Other Routes of Administration (Route of Administration) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 26: Other Routes of Administration (Route of Administration) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 27: Other Routes of Administration (Route of Administration) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
TABLE 28: United States Osteoporosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 29: Osteoporosis Therapeutics Market in the United States by Drug Class:
A Historic Review in US$ Million for 2009-2017
TABLE 30: United States Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 31: United States Osteoporosis Therapeutics Market Estimates and Projections in US$ Million by Route of Administration: 2018 to 2025
TABLE 32: Osteoporosis Therapeutics Market in the United States by Route of Administration: A Historic Review in US$ Million for 2009-2017
TABLE 33: United States Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025
CANADA
TABLE 34: Canadian Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 35: Canadian Osteoporosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 36: Osteoporosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 37: Canadian Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018 to 2025
TABLE 38: Canadian Osteoporosis Therapeutics Historic Market Review by Route of Administration in US$ Million: 2009-2017
TABLE 39: Osteoporosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025
JAPAN
TABLE 40: Japanese Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 41: Osteoporosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 42: Japanese Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 43: Japanese Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Route of Administration for the Period 2018-2025
TABLE 44: Osteoporosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Route of Administration for the Period 2009-2017
TABLE 45: Japanese Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025
CHINA
TABLE 46: Chinese Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 47: Osteoporosis Therapeutics Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017
TABLE 48: Chinese Osteoporosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 49: Chinese Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Route of Administration for the Period 2018-2025
TABLE 50: Osteoporosis Therapeutics Historic Market Analysis in China in US$ Million by Route of Administration: 2009-2017
TABLE 51: Chinese Osteoporosis Therapeutics Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
TABLE 52: European Osteoporosis Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025
TABLE 53: Osteoporosis Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
TABLE 54: European Osteoporosis Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
TABLE 55: European Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 56: Osteoporosis Therapeutics Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 57: European Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 58: European Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018-2025
TABLE 59: Osteoporosis Therapeutics Market in Europe in US$ Million by Route of Administration: A Historic Review for the Period 2009-2017
TABLE 60: European Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025
FRANCE
TABLE 61: Osteoporosis Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 62: French Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 63: French Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 64: Osteoporosis Therapeutics Market in France by Route of Administration: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 65: French Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Route of Administration: 2009-2017
TABLE 66: French Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025
GERMANY
TABLE 67: Osteoporosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 68: German Osteoporosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 69: German Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 70: Osteoporosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Route of Administration for the Period 2018-2025
TABLE 71: German Osteoporosis Therapeutics Historic Market Analysis in US$ Million by Route of Administration: 2009-2017
TABLE 72: German Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025
ITALY
TABLE 73: Italian Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 74: Osteoporosis Therapeutics Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017
TABLE 75: Italian Osteoporosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 76: Italian Osteoporosis Therapeutics Market Growth Prospects in US$ Million by Route of Administration for the Period 2018-2025
TABLE 77: Osteoporosis Therapeutics Historic Market Analysis in Italy in US$ Million by Route of Administration: 2009-2017
TABLE 78: Italian Osteoporosis Therapeutics Market by Route of Administration: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
TABLE 79: United Kingdom Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 80: Osteoporosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 81: United Kingdom Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 82: United Kingdom Market for Osteoporosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Route of Administration for the Period 2018-2025
TABLE 83: Osteoporosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Route of Administration for the Period 2009-2017
TABLE 84: United Kingdom Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025
REST OF EUROPE
TABLE 85: Rest of Europe Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 86: Osteoporosis Therapeutics Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 87: Rest of Europe Osteoporosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 88: Rest of Europe Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018-2025
TABLE 89: Osteoporosis Therapeutics Market in Rest of Europe in US$ Million by Route of Administration: A Historic Review for the Period 2009-2017
TABLE 90: Rest of Europe Osteoporosis Therapeutics Market Share Breakdown by Route of Administration: 2009 VS 2019 VS 2025
ASIA-PACIFIC
TABLE 91: Osteoporosis Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 92: Asia-Pacific Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 93: Asia-Pacific Osteoporosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 94: Osteoporosis Therapeutics Market in Asia-Pacific by Route of Administration: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 95: Asia-Pacific Osteoporosis Therapeutics Historic Market Scenario in US$ Million by Route of Administration: 2009-2017
TABLE 96: Asia-Pacific Osteoporosis Therapeutics Market Share Analysis by Route of Administration: 2009 VS 2019 VS 2025
REST OF WORLD
TABLE 97: Rest of World Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 98: Rest of World Osteoporosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 99: Osteoporosis Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 100: Rest of World Osteoporosis Therapeutics Market Estimates and Forecasts in US$ Million by Route of Administration: 2018 to 2025
TABLE 101: Rest of World Osteoporosis Therapeutics Historic Market Review by Route of Administration in US$ Million: 2009-2017
TABLE 102: Osteoporosis Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Route of Administration for 2009, 2019, and 2025
IV. COMPETITION
1. ALLERGAN PLC
2. AMGEN ASTELLAS BIOPHARMA K.K.
3. AMGEN, INC.
4. ASAHI KASEI PHARMA CORPORATION
5. BONE BIOLOGICS
6. CHUGAI PHARMACEUTICAL CO., LTD.
7. CLINIGEN GROUP PLC
NOVAGEN PHARMA (PTY) LTD.
8. DAIICHI SANKYO CO., LTD.
9. DONG WHA PHARMA CO., LTD.
10. EISAI CO., LTD.
11. ELI LILLY AND COMPANY
ELI LILLY CANADA, INC.
ELI LILLY AND CO., LTD.
ELI LILLY AUSTRALIA
12. ENTERA BIO LTD.
13. ENTERIS BIOPHARMA, INC.
14. ENZO BIOCHEM INC.
15. F. HOFFMANN-LA ROCHE AG
GENENTECH, INC.
16. FLEXION THERAPEUTICS, INC.
17. GEDEON RICHTER PLC
18. HAOMA MEDICA LTD.
19. IMMUNWORK INC.
20. INTAS PHARMACEUTICALS LTD.
21. LIGAND PHARMACEUTICALS INC.
22. LUYE PHARMA GROUP LTD.
23. MABXIENCE HOLDING SL
24. MERCK & CO., INC.
MERCK CANADA INC.
25. NOVARTIS INTERNATIONAL AG
NOVARTIS PHARMACEUTICALS CORPORATION
26. NOVEN PHARMACEUTICALS, INC.
27. ONO PHARMACEUTICAL CO., LTD.
28. PARAS BIOPHARMACEUTICALS FINLAND OY
29. PFENEX, INC.
30. PFIZER, INC.
31. R PHARM JSC
32. RADIUS HEALTH INC.
33. SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.
34. SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
35. SHIN POONG PHARM CO., LTD.
36. SINIL PHARMACEUTICAL CO., LTD.
37. STADA ARZNEIMITTEL AG
38. STELIS BIOPHARMA PVT LTD.
39. TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
40. TAKEDA PHARMACEUTICAL COMPANY LIMITED
41. TEIJIN PHARMA LTD.
42. TZAMAL BIO PHARMA LTD.
43. UNI-BIO SCIENCE GROUP LTD.
44. VIKING THERAPEUTICS, INC.
45. VIROMED CO., LTD.
46. ZYDUS CADILA HEALTHCARE

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook